Avanos Medical (AVNS) Financials

$12.32 -0.17 (-1.32%)

Closing price 05/23/2025 03:59 PM Eastern

Extended Trading

$12.29 -0.02 (-0.19%)

As of 05/23/2025 04:10 PM Eastern

Annual Income Statements for Avanos Medical

This table shows Avanos Medical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-392	-62	51
Consolidated Net Income / (Loss)	-392	-62	51
Net Income / (Loss) Continuing Operations	-386	-9.90	22
Total Pre-Tax Income	-403	-7.90	27
Total Operating Income	-396	4.20	36
Total Gross Profit	381	380	394
Total Revenue	688	673	684
Operating Revenue	688	673	684
Total Cost of Revenue	307	294	290
Operating Cost of Revenue	307	294	290
Total Operating Expenses	778	376	359
Selling, General & Admin Expense	319	335	327
Research & Development Expense	26	27	29
Other Operating Expenses / (Income)	-3.90	13	3.00
Impairment Charge	437	0.00	0.00
Total Other Income / (Expense), net	-7.10	-12	-8.80
Interest Expense	12	15	10
Interest & Investment Income	5.10	2.90	1.20
Income Tax Expense	-17	2.00	5.20
Net Income / (Loss) Discontinued Operations	-5.80	-52	29
Basic Earnings per Share	($8.53)	($1.32)	$1.08
Weighted Average Basic Shares Outstanding	46.00M	46.20M	46.60M
Diluted Earnings per Share	($8.53)	($1.32)	$1.07
Weighted Average Diluted Shares Outstanding	46.00M	46.20M	46.60M
Weighted Average Basic & Diluted Shares Outstanding	46.00M	46.20M	46.60M

This table shows Avanos Medical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-397	4.30	1.80	-0.90	11	-3.70	-68	-0.50	17	16
Consolidated Net Income / (Loss)	-397	4.30	1.80	-0.90	11	-3.70	-68	-0.50	17	16
Net Income / (Loss) Continuing Operations	-397	5.90	4.30	0.50	11	-8.80	-4.30	-7.80	0.30	11
Total Pre-Tax Income	-421	9.50	6.20	1.50	8.90	-2.60	-5.10	-9.10	1.70	10
Total Operating Income	-419	12	6.30	4.00	11	1.20	-2.10	-6.10	4.00	13
Total Gross Profit	98	93	96	95	95	96	98	91	86	100
Total Revenue	180	170	172	166	173	171	169	159	144	172
Operating Revenue	180	170	172	166	173	171	169	159	144	172
Total Cost of Revenue	82	78	76	71	78	76	72	68	58	72
Operating Cost of Revenue	82	78	76	71	78	76	72	68	58	72
Total Operating Expenses	517	81	89	91	84	94	100	98	82	87
Selling, General & Admin Expense	80	74	81	84	75	79	93	89	75	78
Research & Development Expense	5.70	7.20	6.30	7.00	6.80	6.10	6.80	7.50	6.70	7.10
Other Operating Expenses / (Income)	-5.60	-0.60	2.10	0.20	2.50	9.50	0.10	1.20	0.20	2.00
Total Other Income / (Expense), net	-2.00	-2.50	-0.10	-2.50	-2.30	-3.80	-3.00	-3.00	-2.30	-2.70
Interest Expense	2.80	3.20	3.10	3.10	3.30	4.70	3.50	3.50	3.00	3.00
Interest & Investment Income	0.80	0.70	3.00	0.60	1.00	0.90	0.50	0.50	0.70	0.30
Income Tax Expense	-24	3.60	1.90	1.00	-2.10	6.20	-0.80	-1.30	1.40	-0.90
Net Income / (Loss) Discontinued Operations	-0.30	-1.60	-2.50	-1.40	-0.50	5.10	-64	7.30	-	4.70
Basic Earnings per Share	($8.65)	$0.10	$0.04	($0.02)	$0.23	($0.08)	($1.46)	($0.01)	$0.36	$0.34
Weighted Average Basic Shares Outstanding	46.00M	45.96M	45.95M	45.90M	46.20M	46.43M	46.87M	46.67M	46.60M	46.50M
Diluted Earnings per Share	($8.64)	$0.09	$0.04	($0.02)	$0.23	($0.08)	($1.46)	($0.01)	$0.37	$0.33
Weighted Average Diluted Shares Outstanding	46.00M	45.96M	45.95M	45.90M	46.20M	46.43M	46.87M	46.67M	46.60M	46.50M
Weighted Average Basic & Diluted Shares Outstanding	46.00M	45.96M	45.95M	45.90M	46.20M	46.43M	46.87M	46.67M	46.60M	46.50M

This table details how cash moves in and out of Avanos Medical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	20	-40	9.20
Net Cash From Operating Activities	101	32	91
Net Cash From Continuing Operating Activities	101	32	91
Net Income / (Loss) Continuing Operations	-392	-62	51
Consolidated Net Income / (Loss)	-392	-62	51
Depreciation Expense	46	46	48
Non-Cash Adjustments To Reconcile Net Income	452	89	17
Changes in Operating Assets and Liabilities, net	-4.40	-40	-24
Net Cash From Investing Activities	-28	22	-135
Net Cash From Continuing Investing Activities	-28	22	-135
Purchase of Property, Plant & Equipment	-18	-18	-19
Acquisitions	0.00	-50	-116
Divestitures	2.10	89	0.00
Other Investing Activities, net	-12	-	0.00
Net Cash From Financing Activities	-49	-94	57
Net Cash From Continuing Financing Activities	-49	-94	57
Repayment of Debt	-54	-120	-300
Repurchase of Common Equity	-13	-19	-46
Issuance of Debt	20	55	400
Other Financing Activities, net	-2.70	-10	1.70
Effect of Exchange Rate Changes	-4.10	-	-3.00
Cash Interest Paid	12	15	8.10
Cash Income Taxes Paid	-3.30	-24	2.90

This table details how cash moves in and out of Avanos Medical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	19	-3.20	16	-12	-19	25	-14	-32	11	11
Net Cash From Operating Activities	58	23	28	-8.00	13	29	-2.60	-6.80	34	28
Net Cash From Continuing Operating Activities	58	23	28	-8.00	13	29	-2.60	-6.80	34	28
Net Income / (Loss) Continuing Operations	-397	4.30	1.80	-0.90	11	-3.70	-68	-0.50	17	16
Consolidated Net Income / (Loss)	-397	4.30	1.80	-0.90	11	-3.70	-68	-0.50	17	16
Depreciation Expense	11	12	11	11	12	11	12	12	13	12
Non-Cash Adjustments To Reconcile Net Income	441	2.70	3.80	3.90	17	5.00	63	4.00	5.10	4.10
Changes in Operating Assets and Liabilities, net	2.80	4.30	11	-22	-26	17	-9.00	-22	-1.70	-3.00
Net Cash From Investing Activities	-7.60	-12	-5.90	-2.00	81	-49	-6.50	-4.00	-4.90	-4.70
Net Cash From Continuing Investing Activities	-7.60	-12	-5.90	-2.00	81	-49	-6.50	-4.00	-4.90	-4.70
Purchase of Property, Plant & Equipment	-4.80	-3.00	-5.90	-4.10	-5.90	-3.90	-4.00	-4.00	-4.90	-5.30
Other Investing Activities, net	-2.80	-	-	-	-	-	-	-	-	-
Net Cash From Financing Activities	-27	-16	-5.00	-0.70	-115	47	-4.10	-22	-22	-10
Net Cash From Continuing Financing Activities	-27	-16	-5.00	-0.70	-115	47	-4.10	-22	-22	-10
Repayment of Debt	-27	-13	-1.50	-12	-97	-	-1.50	-22	-22	-
Repurchase of Common Equity	-0.10	-0.10	-3.50	-9.10	-6.20	-9.20	-2.60	-1.10	-0.40	-11
Effect of Exchange Rate Changes	-4.20	1.80	-	-	-	-1.60	-	-	3.80	-3.00

This table presents Avanos Medical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	1,154	1,692	1,787
Total Current Assets	393	487	624
Cash & Equivalents	108	88	128
Accounts Receivable	133	143	168
Inventories, net	139	163	132
Prepaid Expenses	14	29	14
Other Current Nonoperating Assets	0.00	65	182
Plant, Property, & Equipment, net	111	117	119
Total Noncurrent Assets	650	1,088	1,044
Goodwill	456	796	760
Intangible Assets	112	240	234
Noncurrent Deferred & Refundable Income Taxes	25	6.50	4.60
Other Noncurrent Operating Assets	57	46	45
Total Liabilities & Shareholders' Equity	1,154	1,692	1,787
Total Liabilities	326	456	496
Total Current Liabilities	166	235	191
Short-Term Debt	9.40	8.60	6.20
Accounts Payable	54	56	68
Accrued Expenses	91	93	98
Other Current Liabilities	11	13	12
Other Current Nonoperating Liabilities	0.00	64	7.10
Total Noncurrent Liabilities	160	222	305
Long-Term Debt	125	159	226
Noncurrent Deferred & Payable Income Tax Liabilities	5.50	24	25
Other Noncurrent Operating Liabilities	29	38	53
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	829	1,236	1,291
Total Preferred & Common Equity	829	1,236	1,291
Preferred Stock	0.00	0.00	0.00
Total Common Equity	829	1,236	1,291
Common Stock	1,679	1,664	1,647
Retained Earnings	-707	-315	-253
Accumulated Other Comprehensive Income / (Loss)	-45	-27	-36
Other Equity Adjustments	-99	-86	-67

This table presents Avanos Medical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	1,656	1,658	1,661	1,725	1,667	1,735	1,775
Total Current Assets	473	474	468	525	507	454	470
Cash & Equivalents	89	92	76	107	82	96	117
Accounts Receivable	132	123	131	145	152	143	146
Inventories, net	162	164	166	157	148	200	194
Prepaid Expenses	16	22	29	14	16	15	13
Other Current Nonoperating Assets	74	73	67	102	109	-	-
Plant, Property, & Equipment, net	110	111	116	117	123	164	163
Total Noncurrent Assets	1,074	1,073	1,077	1,084	1,037	1,118	1,142
Goodwill	795	794	795	792	763	822	824
Intangible Assets	220	226	233	242	223	245	259
Noncurrent Deferred & Refundable Income Taxes	6.60	6.30	6.30	4.30	4.40	4.50	11
Other Noncurrent Operating Assets	52	46	43	46	48	47	49
Total Liabilities & Shareholders' Equity	1,656	1,658	1,661	1,725	1,667	1,735	1,775
Total Liabilities	427	436	433	503	432	436	512
Total Current Liabilities	213	208	205	171	161	159	162
Short-Term Debt	9.40	10	9.40	6.20	6.20	6.20	6.20
Accounts Payable	54	51	57	52	65	60	63
Accrued Expenses	83	80	75	97	73	81	80
Other Current Liabilities	14	14	12	13	14	12	13
Other Current Nonoperating Liabilities	53	53	52	2.50	2.70	-	-
Total Noncurrent Liabilities	214	228	228	332	271	278	349
Long-Term Debt	153	165	167	258	203	205	248
Noncurrent Deferred & Payable Income Tax Liabilities	24	23	24	29	22	25	37
Other Noncurrent Operating Liabilities	37	39	37	45	46	48	65
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,230	1,222	1,228	1,222	1,235	1,299	1,264
Total Preferred & Common Equity	1,230	1,222	1,228	1,222	1,235	1,299	1,264
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,230	1,222	1,228	1,222	1,235	1,299	1,264
Common Stock	1,675	1,672	1,668	1,660	1,655	1,652	1,643
Retained Earnings	-310	-314	-316	-325	-322	-254	-270
Accumulated Other Comprehensive Income / (Loss)	-37	-38	-30	-33	-28	-31	-43
Other Equity Adjustments	-99	-99	-95	-80	-71	-68	-

This table displays calculated financial ratios and metrics derived from Avanos Medical's official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	2.15%	-1.58%	16.54%
EBITDA Growth	-797.22%	-39.54%	11,985.71%
EBIT Growth	-9,533.33%	-88.17%	191.03%
NOPAT Growth	-9,533.33%	-89.72%	204.71%
Net Income Growth	-534.47%	-222.38%	701.59%
EPS Growth	-546.21%	-223.36%	723.08%
Operating Cash Flow Growth	210.80%	-64.36%	4.12%
Free Cash Flow Firm Growth	298.74%	-202.42%	476.19%
Invested Capital Growth	-34.98%	7.78%	-4.78%
Revenue Q/Q Growth	0.92%	4.63%	18.68%
EBITDA Q/Q Growth	-541.69%	11.78%	58.17%
EBIT Q/Q Growth	-1,282.69%	240.00%	303.41%
NOPAT Q/Q Growth	-1,095.75%	240.00%	210.58%
Net Income Q/Q Growth	-2,597.45%	-11.55%	12.47%
EPS Q/Q Growth	-2,608.82%	-11.86%	13.83%
Operating Cash Flow Q/Q Growth	81.44%	-39.33%	-16.83%
Free Cash Flow Firm Q/Q Growth	602.27%	-177.69%	176.66%
Invested Capital Q/Q Growth	-33.25%	2.80%	-12.83%
Profitability Metrics	-	-	-
Gross Margin	55.44%	56.39%	57.62%
EBITDA Margin	-50.99%	7.47%	12.16%
Operating Margin	-57.60%	0.62%	5.19%
EBIT Margin	-57.60%	0.62%	5.19%
Profit (Net Income) Margin	-57.01%	-9.18%	7.38%
Tax Burden Percent	97.22%	782.28%	189.14%
Interest Burden Percent	101.79%	-188.10%	75.21%
Effective Tax Rate	0.00%	0.00%	19.48%
Return on Invested Capital (ROIC)	-25.55%	0.23%	2.28%
ROIC Less NNEP Spread (ROIC-NNEP)	-241.06%	-1,422.63%	-72.13%
Return on Net Nonoperating Assets (RNNOA)	-12.43%	-5.12%	1.66%
Return on Equity (ROE)	-37.98%	-4.89%	3.94%
Cash Return on Invested Capital (CROIC)	16.85%	-7.26%	7.18%
Operating Return on Assets (OROA)	-27.84%	0.24%	2.09%
Return on Assets (ROA)	-27.55%	-3.55%	2.98%
Return on Common Equity (ROCE)	-37.98%	-4.89%	3.94%
Return on Equity Simple (ROE_SIMPLE)	-47.33%	-5.00%	3.91%
Net Operating Profit after Tax (NOPAT)	-277	2.94	29
NOPAT Margin	-40.32%	0.44%	4.18%
Net Nonoperating Expense Percent (NNEP)	215.51%	1,422.86%	74.41%
Return On Investment Capital (ROIC_SIMPLE)	-28.79%	0.21%	1.88%
Cost of Revenue to Revenue	44.56%	43.61%	42.38%
SG&A Expenses to Revenue	46.31%	49.75%	47.73%
R&D to Revenue	3.81%	4.04%	4.27%
Operating Expenses to Revenue	113.04%	55.77%	52.43%
Earnings before Interest and Taxes (EBIT)	-396	4.20	36
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-351	50	83
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	0.88	0.84	0.97
Price to Tangible Book Value (P/TBV)	2.81	5.19	4.24
Price to Revenue (P/Rev)	1.06	1.55	1.84
Price to Earnings (P/E)	0.00	0.00	24.92
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	4.01%
Enterprise Value to Invested Capital (EV/IC)	0.89	0.85	1.12
Enterprise Value to Revenue (EV/Rev)	1.10	1.67	1.99
Enterprise Value to EBITDA (EV/EBITDA)	0.00	22.30	16.38
Enterprise Value to EBIT (EV/EBIT)	0.00	267.05	38.40
Enterprise Value to NOPAT (EV/NOPAT)	0.00	381.51	47.68
Enterprise Value to Operating Cash Flow (EV/OCF)	7.53	34.62	14.99
Enterprise Value to Free Cash Flow (EV/FCFF)	4.15	0.00	15.16
Leverage & Solvency	-	-	-
Debt to Equity	0.16	0.14	0.18
Long-Term Debt to Equity	0.15	0.13	0.18
Financial Leverage	0.05	0.00	-0.02
Leverage Ratio	1.38	1.38	1.32
Compound Leverage Factor	1.40	-2.59	1.00
Debt to Total Capital	13.98%	11.96%	15.26%
Short-Term Debt to Total Capital	0.98%	0.61%	0.41%
Long-Term Debt to Total Capital	13.01%	11.35%	14.85%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	86.02%	88.04%	84.74%
Debt to EBITDA	-0.38	3.34	2.79
Net Debt to EBITDA	-0.08	1.60	1.26
Long-Term Debt to EBITDA	-0.36	3.17	2.72
Debt to NOPAT	-0.49	57.14	8.13
Net Debt to NOPAT	-0.10	27.31	3.67
Long-Term Debt to NOPAT	-0.45	54.22	7.92
Altman Z-Score	0.19	1.69	2.06
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	2.37	2.08	3.27
Quick Ratio	1.45	0.98	1.55
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	183	-92	90
Operating Cash Flow to CapEx	565.73%	182.02%	470.98%
Free Cash Flow to Firm to Interest Expense	15.00	-6.14	8.99
Operating Cash Flow to Interest Expense	8.25	2.16	9.09
Operating Cash Flow Less CapEx to Interest Expense	6.80	0.97	7.16
Efficiency Ratios	-	-	-
Asset Turnover	0.48	0.39	0.40
Accounts Receivable Turnover	4.99	4.33	4.57
Inventory Turnover	2.03	1.99	1.99
Fixed Asset Turnover	6.04	5.71	4.77
Accounts Payable Turnover	5.54	4.73	4.66
Days Sales Outstanding (DSO)	73.13	84.22	79.79
Days Inventory Outstanding (DIO)	179.82	183.68	183.57
Days Payable Outstanding (DPO)	65.85	77.20	78.25
Cash Conversion Cycle (CCC)	187.09	190.70	185.11
Capital & Investment Metrics	-	-	-
Invested Capital	856	1,316	1,221
Invested Capital Turnover	0.63	0.53	0.55
Increase / (Decrease) in Invested Capital	-460	95	-61
Enterprise Value (EV)	759	1,122	1,363
Market Capitalization	732	1,041	1,258
Book Value per Share	$18.03	$26.63	$27.77
Tangible Book Value per Share	$5.67	$4.32	$6.38
Total Capital	963	1,404	1,524
Total Debt	135	168	233
Total Long-Term Debt	125	159	226
Net Debt	27	80	105
Capital Expenditures (CapEx)	18	18	19
Debt-free, Cash-free Net Working Capital (DFCFNWC)	129	173	312
Debt-free Net Working Capital (DFNWC)	237	261	439
Net Working Capital (NWC)	228	252	433
Net Nonoperating Expense (NNE)	115	65	-22
Net Nonoperating Obligations (NNO)	27	80	-70
Total Depreciation and Amortization (D&A)	46	46	48
Debt-free, Cash-free Net Working Capital to Revenue	18.78%	25.74%	45.55%
Debt-free Net Working Capital to Revenue	34.44%	38.76%	64.22%
Net Working Capital to Revenue	33.08%	37.49%	63.31%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($8.53)	($1.32)	$1.08
Adjusted Weighted Average Basic Shares Outstanding	46.00M	46.20M	46.60M
Adjusted Diluted Earnings per Share	($8.53)	($1.32)	$1.07
Adjusted Weighted Average Diluted Shares Outstanding	46.00M	46.20M	46.60M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	46.00M	46.20M	46.60M
Normalized Net Operating Profit after Tax (NOPAT)	28	2.94	29
Normalized NOPAT Margin	4.12%	0.44%	4.18%
Pre Tax Income Margin	-58.64%	-1.17%	3.90%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-32.48	0.28	3.55
NOPAT to Interest Expense	-22.73	0.20	2.86
EBIT Less CapEx to Interest Expense	-33.93	-0.91	1.62
NOPAT Less CapEx to Interest Expense	-24.19	-0.99	0.93
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	-3.26%	-30.91%	90.10%

This table displays calculated financial ratios and metrics derived from Avanos Medical's official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	3.64%	-0.53%	1.36%	4.27%	20.77%	-0.58%	-0.88%	-19.30%	300.84%	-6.41%
EBITDA Growth	-1,894.71%	94.26%	87.23%	156.67%	30.46%	-50.00%	-56.68%	-69.54%	231.82%	87.69%
EBIT Growth	-3,836.61%	900.00%	400.00%	165.57%	180.00%	-90.63%	-120.79%	-170.93%	117.62%	276.47%
NOPAT Growth	-2,216.28%	787.22%	397.24%	131.23%	1,861.05%	-93.97%	-123.04%	-167.12%	104.44%	131.36%
Net Income Growth	-3,883.81%	216.22%	102.64%	-80.00%	-37.87%	-123.57%	-644.80%	-109.26%	49.56%	144.48%
EPS Growth	-3,856.52%	212.50%	102.74%	-100.00%	-37.84%	-124.24%	-661.54%	-109.09%	54.17%	145.21%
Operating Cash Flow Growth	355.91%	-20.96%	1,169.23%	-17.65%	-62.31%	2.46%	-109.63%	-477.78%	-35.32%	22.41%
Free Cash Flow Firm Growth	306.20%	-95.35%	-117.03%	971.51%	-230.89%	256.78%	550.59%	84.09%	129.57%	-1,697.71%
Invested Capital Growth	-34.98%	0.14%	2.26%	-7.04%	7.78%	-8.61%	-10.19%	0.52%	-4.78%	6.98%
Revenue Q/Q Growth	5.40%	-0.76%	3.37%	-4.15%	1.17%	1.12%	6.34%	11.01%	-16.72%	0.82%
EBITDA Q/Q Growth	-1,818.99%	34.66%	14.29%	-32.16%	86.07%	29.79%	56.67%	-65.52%	-28.69%	12.44%
EBIT Q/Q Growth	-3,587.50%	90.48%	57.50%	-64.29%	833.33%	157.14%	65.57%	-252.50%	-68.75%	26.73%
NOPAT Q/Q Growth	-4,030.83%	70.57%	227.70%	-90.37%	1,547.94%	157.14%	65.57%	-704.92%	-94.94%	118.54%
Net Income Q/Q Growth	-9,339.53%	138.89%	300.00%	-108.57%	383.78%	94.57%	-13,520.00%	-102.96%	7.64%	25.60%
EPS Q/Q Growth	-9,700.00%	125.00%	300.00%	-108.70%	387.50%	94.52%	-14,500.00%	-102.70%	12.12%	26.92%
Operating Cash Flow Q/Q Growth	151.74%	-17.27%	447.50%	-162.99%	-56.36%	1,219.23%	61.76%	-120.18%	18.66%	5.19%
Free Cash Flow Firm Q/Q Growth	2,860.57%	123.52%	-123.83%	224.24%	-166.83%	-13.95%	1,319.79%	-118.66%	180.05%	-147.31%
Invested Capital Q/Q Growth	-33.25%	-0.25%	-2.24%	-0.11%	2.80%	1.86%	-11.13%	15.82%	-12.83%	0.10%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	54.57%	54.52%	55.68%	57.07%	54.82%	55.75%	57.73%	57.38%	59.79%	58.15%
EBITDA Margin	-226.84%	13.91%	10.25%	9.27%	13.10%	7.12%	5.55%	3.77%	12.13%	14.16%
Operating Margin	-233.02%	7.04%	3.67%	2.41%	6.46%	0.70%	-1.24%	-3.83%	2.79%	7.43%
EBIT Margin	-233.02%	7.04%	3.67%	2.41%	6.46%	0.70%	-1.24%	-3.83%	2.79%	7.43%
Profit (Net Income) Margin	-221.21%	2.52%	1.05%	-0.54%	6.06%	-2.16%	-40.20%	-0.31%	11.78%	9.11%
Tax Burden Percent	94.48%	45.26%	29.03%	-60.00%	117.98%	142.31%	1,335.29%	5.49%	994.12%	155.45%
Interest Burden Percent	100.48%	79.17%	98.41%	37.50%	79.46%	-216.67%	242.86%	149.18%	42.50%	78.91%
Effective Tax Rate	0.00%	37.89%	30.65%	66.67%	-23.60%	0.00%	0.00%	0.00%	82.35%	-8.91%
Return on Invested Capital (ROIC)	-103.34%	2.33%	1.37%	0.40%	4.24%	0.24%	-0.42%	-1.23%	0.27%	3.44%
ROIC Less NNEP Spread (ROIC-NNEP)	-299.30%	-3.42%	-4.71%	-1.81%	-69.23%	-4.43%	-79.18%	1.61%	-54.72%	5.35%
Return on Net Nonoperating Assets (RNNOA)	-15.44%	-0.15%	-0.16%	-0.14%	-0.25%	-0.35%	-5.39%	0.17%	1.26%	0.39%
Return on Equity (ROE)	-118.78%	2.17%	1.20%	0.26%	3.99%	-0.11%	-5.81%	-1.06%	1.53%	3.83%
Cash Return on Invested Capital (CROIC)	16.85%	2.03%	-1.34%	6.67%	-7.26%	8.84%	11.19%	0.67%	7.18%	-8.65%
Operating Return on Assets (OROA)	-112.60%	2.84%	1.51%	0.96%	2.50%	0.26%	-0.47%	-1.41%	1.12%	2.54%
Return on Assets (ROA)	-106.90%	1.02%	0.43%	-0.22%	2.35%	-0.79%	-15.15%	-0.12%	4.75%	3.11%
Return on Common Equity (ROCE)	-118.78%	2.17%	1.20%	0.26%	3.99%	-0.11%	-5.81%	-1.06%	1.53%	3.83%
Return on Equity Simple (ROE_SIMPLE)	0.00%	1.28%	0.63%	-5.07%	0.00%	-4.53%	-2.92%	3.43%	0.00%	3.55%
Net Operating Profit after Tax (NOPAT)	-293	7.45	4.37	1.33	14	0.84	-1.47	-4.27	0.71	14
NOPAT Margin	-163.11%	4.37%	2.54%	0.80%	7.99%	0.49%	-0.87%	-2.68%	0.49%	8.09%
Net Nonoperating Expense Percent (NNEP)	195.96%	5.74%	6.07%	2.21%	73.47%	4.66%	78.76%	-2.84%	54.99%	-1.91%
Return On Investment Capital (ROIC_SIMPLE)	-30.41%	-	-	-	0.99%	-	-	-	0.05%	-
Cost of Revenue to Revenue	45.43%	45.48%	44.32%	42.93%	45.18%	44.25%	42.27%	42.62%	40.21%	41.85%
SG&A Expenses to Revenue	44.38%	43.60%	47.12%	50.33%	42.99%	45.94%	54.90%	55.74%	52.20%	45.44%
R&D to Revenue	3.17%	4.23%	3.67%	4.21%	3.92%	3.56%	4.01%	4.71%	4.67%	4.12%
Operating Expenses to Revenue	287.58%	47.48%	52.01%	54.67%	48.36%	55.05%	58.97%	61.21%	57.00%	50.73%
Earnings before Interest and Taxes (EBIT)	-419	12	6.30	4.00	11	1.20	-2.10	-6.10	4.00	13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-407	24	18	15	23	12	9.40	6.00	17	24
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.88	0.90	0.75	0.75	0.84	0.78	0.97	1.07	0.97	0.80
Price to Tangible Book Value (P/TBV)	2.81	5.15	4.54	4.62	5.19	5.03	4.78	5.96	4.24	5.59
Price to Revenue (P/Rev)	1.06	1.62	1.34	1.36	1.55	1.47	1.85	2.15	1.84	1.76
Price to Earnings (P/E)	0.00	70.33	118.75	0.00	0.00	0.00	0.00	31.07	24.92	22.55
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	1.42%	0.84%	0.00%	0.00%	0.00%	0.00%	3.22%	4.01%	4.43%
Enterprise Value to Invested Capital (EV/IC)	0.89	0.92	0.78	0.78	0.85	0.86	1.05	1.06	1.12	0.82
Enterprise Value to Revenue (EV/Rev)	1.10	1.73	1.46	1.51	1.67	1.72	2.05	2.32	1.99	1.99
Enterprise Value to EBITDA (EV/EBITDA)	0.00	14.83	14.69	17.17	22.30	24.56	23.09	21.60	16.38	21.85
Enterprise Value to EBIT (EV/EBIT)	0.00	35.14	43.93	71.69	267.05	0.00	153.55	72.17	38.40	130.62
Enterprise Value to NOPAT (EV/NOPAT)	0.00	42.26	87.87	0.00	381.51	0.00	219.35	89.56	47.68	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	7.53	21.21	16.19	32.86	34.62	20.70	25.06	18.24	14.99	10.52
Enterprise Value to Free Cash Flow (EV/FCFF)	4.15	45.18	0.00	11.26	0.00	9.33	8.89	158.65	15.16	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.16	0.13	0.14	0.14	0.14	0.22	0.17	0.16	0.18	0.20
Long-Term Debt to Equity	0.15	0.12	0.13	0.14	0.13	0.21	0.16	0.16	0.18	0.20
Financial Leverage	0.05	0.04	0.03	0.08	0.00	0.08	0.07	0.10	-0.02	0.07
Leverage Ratio	1.38	1.38	1.35	1.34	1.38	1.41	1.38	1.37	1.32	1.34
Compound Leverage Factor	1.39	1.09	1.33	0.50	1.09	-3.05	3.34	2.04	0.56	1.05
Debt to Total Capital	13.98%	11.64%	12.53%	12.57%	11.96%	17.79%	14.51%	13.97%	15.26%	16.74%
Short-Term Debt to Total Capital	0.98%	0.68%	0.73%	0.67%	0.61%	0.42%	0.43%	0.41%	0.41%	0.41%
Long-Term Debt to Total Capital	13.01%	10.97%	11.80%	11.90%	11.35%	17.38%	14.08%	13.56%	14.85%	16.33%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	86.02%	88.36%	87.47%	87.43%	88.04%	82.21%	85.49%	86.03%	84.74%	83.26%
Debt to EBITDA	-0.38	2.04	2.58	2.96	3.34	5.88	3.66	3.03	2.79	4.83
Net Debt to EBITDA	-0.08	0.92	1.22	1.69	1.60	3.50	2.23	1.66	1.26	2.60
Long-Term Debt to EBITDA	-0.36	1.92	2.43	2.80	3.17	5.74	3.55	2.95	2.72	4.71
Debt to NOPAT	-0.49	5.82	15.43	-20.84	57.14	-125.95	34.80	12.58	8.13	-9.83
Net Debt to NOPAT	-0.10	2.62	7.30	-11.90	27.31	-74.95	21.21	6.87	3.67	-5.30
Long-Term Debt to NOPAT	-0.45	5.48	14.53	-19.73	54.22	-123.00	33.77	12.21	7.92	-9.59
Altman Z-Score	0.13	1.92	1.61	1.62	1.71	1.49	2.02	2.27	2.01	1.53
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.37	2.22	2.28	2.28	2.08	3.07	3.16	2.86	3.27	2.90
Quick Ratio	1.45	1.04	1.03	1.01	0.98	1.48	1.46	1.50	1.55	1.62
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	167	5.65	-24	101	-81	121	141	-12	62	-77
Operating Cash Flow to CapEx	1,206.25%	766.67%	471.19%	-195.12%	215.25%	746.15%	-65.00%	-170.00%	687.76%	535.85%
Free Cash Flow to Firm to Interest Expense	59.77	1.77	-7.75	32.53	-24.59	25.84	40.32	-3.31	20.67	-25.82
Operating Cash Flow to Interest Expense	20.68	7.19	8.97	-2.58	3.85	6.19	-0.74	-1.94	11.23	9.47
Operating Cash Flow Less CapEx to Interest Expense	18.96	6.25	7.06	-3.90	2.06	5.36	-1.89	-3.09	9.60	7.70
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.48	0.40	0.41	0.40	0.39	0.37	0.38	0.37	0.40	0.34
Accounts Receivable Turnover	4.99	4.92	4.96	4.96	4.33	4.42	4.33	4.25	4.57	4.37
Inventory Turnover	2.03	1.90	1.93	1.62	1.99	1.56	1.70	1.49	1.99	1.34
Fixed Asset Turnover	6.04	6.02	5.85	4.86	5.71	4.59	4.49	3.91	4.77	3.46
Accounts Payable Turnover	5.54	5.70	5.16	5.09	4.73	4.76	4.16	4.33	4.66	4.01
Days Sales Outstanding (DSO)	73.13	74.21	73.63	73.53	84.22	82.64	84.30	85.97	79.79	83.49
Days Inventory Outstanding (DIO)	179.82	191.71	188.98	224.65	183.68	234.11	215.03	244.43	183.57	272.20
Days Payable Outstanding (DPO)	65.85	63.98	70.70	71.65	77.20	76.74	87.83	84.35	78.25	90.94
Cash Conversion Cycle (CCC)	187.09	201.93	191.90	226.53	190.70	240.01	211.50	246.05	185.11	264.76
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	856	1,282	1,285	1,314	1,316	1,280	1,257	1,414	1,221	1,401
Invested Capital Turnover	0.63	0.53	0.54	0.50	0.53	0.48	0.49	0.46	0.55	0.43
Increase / (Decrease) in Invested Capital	-460	1.80	28	-100	95	-121	-143	7.30	-61	91
Enterprise Value (EV)	759	1,177	997	1,025	1,122	1,105	1,321	1,501	1,363	1,149
Market Capitalization	732	1,104	914	924	1,041	948	1,193	1,386	1,258	1,012
Book Value per Share	$18.03	$26.76	$26.62	$26.75	$26.63	$26.07	$26.46	$27.87	$27.77	$27.18
Tangible Book Value per Share	$5.67	$4.67	$4.39	$4.36	$4.32	$4.02	$5.35	$4.99	$6.38	$3.90
Total Capital	963	1,392	1,397	1,405	1,404	1,487	1,444	1,510	1,524	1,518
Total Debt	135	162	175	177	168	265	210	211	233	254
Total Long-Term Debt	125	153	165	167	159	258	203	205	226	248
Net Debt	27	73	83	101	80	157	128	115	105	137
Capital Expenditures (CapEx)	4.80	3.00	5.90	4.10	5.90	3.90	4.00	4.00	4.90	5.30
Debt-free, Cash-free Net Working Capital (DFCFNWC)	129	180	184	196	173	253	271	206	312	197
Debt-free Net Working Capital (DFNWC)	237	269	276	272	261	360	353	302	439	314
Net Working Capital (NWC)	228	260	266	263	252	354	346	295	433	308
Net Nonoperating Expense (NNE)	104	3.15	2.57	2.23	3.34	4.54	67	-3.77	-16	-1.76
Net Nonoperating Obligations (NNO)	27	52	63	87	80	58	22	115	-70	137
Total Depreciation and Amortization (D&A)	11	12	11	11	12	11	12	12	13	12
Debt-free, Cash-free Net Working Capital to Revenue	18.78%	26.43%	26.95%	28.85%	25.74%	39.32%	42.02%	31.86%	45.55%	34.16%
Debt-free Net Working Capital to Revenue	34.44%	39.49%	40.46%	39.99%	38.76%	55.96%	54.71%	46.67%	64.22%	54.46%
Net Working Capital to Revenue	33.08%	38.11%	38.97%	38.61%	37.49%	55.00%	53.75%	45.71%	63.31%	53.38%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($8.65)	$0.10	$0.04	($0.02)	$0.23	($0.08)	($1.46)	($0.01)	$0.36	$0.34
Adjusted Weighted Average Basic Shares Outstanding	46.00M	45.96M	45.95M	45.90M	46.20M	46.43M	46.87M	46.67M	46.60M	46.50M
Adjusted Diluted Earnings per Share	($8.64)	$0.09	$0.04	($0.02)	$0.23	($0.08)	($1.46)	($0.01)	$0.37	$0.33
Adjusted Weighted Average Diluted Shares Outstanding	46.00M	45.96M	45.95M	45.90M	46.20M	46.43M	46.87M	46.67M	46.60M	46.50M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	46.00M	45.96M	45.95M	45.90M	46.20M	46.43M	46.87M	46.67M	46.60M	46.50M
Normalized Net Operating Profit after Tax (NOPAT)	-293	7.45	4.37	2.80	7.84	0.84	-1.47	-4.27	2.80	8.96
Normalized NOPAT Margin	-163.11%	4.37%	2.54%	1.69%	4.52%	0.49%	-0.87%	-2.68%	1.95%	5.20%
Pre Tax Income Margin	-234.13%	5.58%	3.61%	0.90%	5.14%	-1.52%	-3.01%	-5.71%	1.18%	5.86%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-149.46	3.75	2.03	1.29	3.39	0.26	-0.60	-1.74	1.33	4.27
NOPAT to Interest Expense	-104.63	2.33	1.41	0.43	4.19	0.18	-0.42	-1.22	0.24	4.65
EBIT Less CapEx to Interest Expense	-151.18	2.81	0.13	-0.03	1.61	-0.57	-1.74	-2.89	-0.30	2.50
NOPAT Less CapEx to Interest Expense	-106.34	1.39	-0.49	-0.89	2.41	-0.65	-1.56	-2.36	-1.40	2.88
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-3.26%	120.38%	363.64%	-43.57%	-30.91%	-24.01%	-41.94%	60.99%	90.10%	124.72%

Frequently Asked Questions About Avanos Medical's Financials

When does Avanos Medical's fiscal year end?

According to the most recent income statement we have on file, Avanos Medical's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Avanos Medical's net income changed over the last 2 years?

Avanos Medical's net income appears to be on an upward trend, with a most recent value of -$392.10 million in 2024, falling from $50.50 million in 2022. The previous period was -$61.80 million in 2023.

What is Avanos Medical's operating income?

Avanos Medical's total operating income in 2024 was -$396.20 million, based on the following breakdown:

Total Gross Profit: $381.30 million
Total Operating Expenses: $777.50 million

How has Avanos Medical revenue changed over the last 2 years?

Over the last 2 years, Avanos Medical's total revenue changed from $684.10 million in 2022 to $687.80 million in 2024, a change of 0.5%.

How much debt does Avanos Medical have?

Avanos Medical's total liabilities were at $325.70 million at the end of 2024, a 28.6% decrease from 2023, and a 34.3% decrease since 2022.

How much cash does Avanos Medical have?

In the past 2 years, Avanos Medical's cash and equivalents has ranged from $87.70 million in 2023 to $127.70 million in 2022, and is currently $107.70 million as of their latest financial filing in 2024.

How has Avanos Medical's book value per share changed over the last 2 years?

Over the last 2 years, Avanos Medical's book value per share changed from 27.77 in 2022 to 18.03 in 2024, a change of -35.1%.

Related Companies

This page (NYSE:AVNS) was last updated on 5/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avanos Medical (AVNS) Financials

Frequently Asked Questions About Avanos Medical's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avanos Medical (AVNS) Financials

Annual Income Statements for Avanos Medical

Quarterly Income Statements for Avanos Medical

Annual Cash Flow Statements for Avanos Medical

Quarterly Cash Flow Statements for Avanos Medical

Annual Balance Sheets for Avanos Medical

Quarterly Balance Sheets for Avanos Medical

Annual Metrics And Ratios for Avanos Medical

Quarterly Metrics And Ratios for Avanos Medical

Frequently Asked Questions About Avanos Medical's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools